J. Safra Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

J. Safra Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13	Closed	-$5K	–	150
2022 Q1	$5K	Sell	13 -14	-52%	-$44	0.09%	20
2021 Q4	$6K	Sell	27 -5,953	-100%	-$37K	0.12%	22
2021 Q3	$45K	Hold	5,980	–	–	0.01%	25
2021 Q2	$76K	Hold	5,980	–	–	0.04%	31
2021 Q1	$49K	Hold	5,980	–	–	0.02%	32
2020 Q4	$41K	Hold	5,980	–	–	0.02%	30
2020 Q3	$67K	Hold	5,980	–	–	0.04%	16
2020 Q2	$37K	Buy	+5,980	New	+$22.9K	0.03%	17

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

J. Safra Asset Management's SRNE Position: Q2 2022 in Review

J. Safra Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 13 shares — an estimated $5K sold.

J. Safra Asset Management first reported a position in SRNE in Q2 2020 and held it in 8 quarters. The position peaked at $76K in Q2 2021. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

J. Safra Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
J. Safra Asset Management sold 13 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $5K.
J. Safra Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 8 quarters.
J. Safra Asset Management's Sorrento Therapeutics, Inc. position peaked at $76K in Q2 2021.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on J. Safra Asset Management's 13F filing for Q2 2022, filed 1 Aug 2022.